REG - Alliance Pharma PLC - Total Voting Rights

Alliance PharmaAnnouncement

01/12/2021 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211201:nRSA2520Ua&default-theme=true

RNS Number : 2520U  Alliance Pharma PLC  01 December 2021

 For immediate release
                        1 December 2021

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Total Voting Rights

 

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the
following notification in accordance with the UK Financial Conduct Authority's
Disclosure and Transparency Rule 5.6.1.

As at 30 November 2021 the Company's issued share capital consists of
538,044,717 Ordinary Shares of 1p each.

 

The total number of voting rights in the Company is 538,044,717 and this
figure may be used by shareholders as the denominator for the calculations by
which they should determine if they are required to notify their interest in,
or change to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.

 

For further information:

 

 Alliance Pharma plc                                     + 44 (0)1249 466966
 Peter Butterfield, Chief Executive Officer
 Andrew Franklin, Chief Financial Officer
 www.alliancepharma.co.uk
 Buchanan                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff

 Numis Securities Limited                                + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 

 Investec Bank plc                + 44 (0) 20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com (http://www.alliancepharmaceuticals.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREADAFEDPFFFA